High-dose Cytarabine and Survival in AML

Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC

NCT00180167 ·Status: COMPLETED ·Phase: PHASE4

A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia

NCT00400673 ·Status: COMPLETED ·Phase: PHASE2

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

NCT03012672 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

NCT00002719 ·Status: COMPLETED ·Phase: PHASE3

Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.

NCT03350152 ·Status: COMPLETED

Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)

NCT00880243 ·Status: COMPLETED ·Phase: PHASE3

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

NCT00131027 ·Status: UNKNOWN ·Phase: PHASE3

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

NCT02926586 ·Status: COMPLETED ·Phase: PHASE4

Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

NCT04914676 ·Status: TERMINATED ·Phase: PHASE2

Risk-adapted Therapy for Primary Acute Myeloid Leukemia

NCT04687098 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

NCT04415008 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

NCT06621199 ·Status: RECRUITING ·Phase: PHASE2

Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia

NCT02844257 ·Status: COMPLETED

AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients

NCT02440568 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)

NCT01145846 ·Status: UNKNOWN ·Phase: PHASE3

Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

NCT00513305 ·Status: TERMINATED ·Phase: PHASE3

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

NCT02416388 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

NCT00422591 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

NCT06232694 ·Status: RECRUITING ·Phase: NA

Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia

NCT01700413 ·Status: COMPLETED ·Phase: PHASE2

Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML

NCT06758726 ·Status: NOT_YET_RECRUITING ·Phase: NA

3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia

NCT01587430 ·Status: UNKNOWN ·Phase: PHASE4

Daunorubicin + Cytarabine + Venetoclax in de Novo AML

NCT06697327 ·Status: ENROLLING_BY_INVITATION ·Phase: NA

Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .

NCT07343687 ·Status: NOT_YET_RECRUITING

Risk-adapted Therapy for Adult Acute Myeloid Leukemia.

NCT01716793 ·Status: COMPLETED ·Phase: PHASE2